Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

Masimo Corporation designs, develops, and licenses medical signal processing and sensor technology for the non-invasive monitoring of physiological parameters. The Company"s products are designed to improve the effectiveness of pulse oximetry by overcoming the inability of current monitors to precisely measure the levels of arterial blood oxygen saturation and low arterial blood flow.
Website: masimo.com



Growth: Good revenue growth rate 78.8%, there is acceleration compared to average historical growth rates 24.9%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -58.4%

Profitability: LTM EBITDA margin is positive, +14.3%. On average the margin is decreasing unsteadily. Gross margin is high, +51.4%. In the last quarter the company beat the estimated EPS, +4.8%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.10 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -12.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 75.6% higher than minimum and 55.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.3x by EV / Sales multiple , the company can be 9.4% overvalued

Key Financials (Download financials)

Ticker: MASI
Share price, USD:  (-0.8%)134.77
year average price 125.83  


year start price 196.03 2023-04-22

max close price 196.06 2023-04-24

min close price 76.73 2023-10-16

current price 134.77 2024-04-20
Common stocks: 55 504 400

Dividend Yield:  0.0%
FCF Yield LTM: -12.8%
EV / LTM EBITDA: 33.0x
EV / EBITDA annualized: 31.1x
Last revenue growth (y/y):  78.8%
Last growth of EBITDA (y/y):  -16.5%
Historical revenue growth:  24.9%
Historical growth of EBITDA:  2.4%
EV / Sales: 4.7x
Margin (EBITDA LTM / Revenue): 14.3%
Fundamental value created in LTM:
Market Cap ($m): 7 480
Net Debt ($m): 732
EV (Enterprise Value): 8 212
Price to Book: 5.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-19Zacks Investment Research

Will Masimo (MASI) Beat Estimates Again in Its Next Earnings Report?

2024-04-19Zacks Investment Research

Reasons Why You Should Retain Masimo (MASI) Stock for Now

2024-04-17Zacks Investment Research

Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?

2024-04-10Forbes

Masimo To Explore Spin-Off Of Its Consumer Unit

2024-03-27Zacks Investment Research

Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?

2024-03-27Zacks Investment Research

Masimo (MASI) Plans Consumer Business Spin-Off to Drive Growth

2024-03-26Zacks Investment Research

Masimo (MASI) Soars 3.3%: Is Further Upside Left in the Stock?

2024-03-25CNBC Television

Masimo CEO on potential split, proxy battle and spinning off consumer business

2024-03-25CNBC

Activist investor plans second fight at Masimo, sending shares up 12%

2024-03-25Market Watch

Masimo's stock rallies on report of looming activist campaign, disclosure of spinoff plan
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-30 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-10-01
symbol MASI MASI MASI MASI MASI MASI
reportedCurrency USD USD USD USD USD USD
cik 937 556 937 556 937 556 937 556 937 556 937 556
fillingDate 2024-02-28 2023-11-08 2023-08-08 2023-05-10 2023-03-01 2022-11-09
acceptedDate 2024-02-28 17:31:44 2023-11-07 19:39:46 2023-08-08 17:30:23 2023-05-09 21:23:27 2023-03-01 07:24:40 2022-11-08 17:47:45
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 549M 479M 455M 565M 617M 549M
costOfRevenue 286M 244M 234M 280M 304M 267M
grossProfit 263M 235M 221M 285M 313M 283M
grossProfitRatio 0.479 0.490 0.486 0.504 0.508 0.514
researchAndDevelopmentExpenses 38M 47M 40M 51M 54M 53M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 160M 156M 152M 196M 186M 175M
otherExpenses 21M -11M -5M -12M 0 0
operatingExpenses 198M 203M 192M 247M 240M 228M
costAndExpenses 484M 447M 426M 527M 544M 495M
interestIncome 800 000 700 000 700 000 800 000 800 000 500 000
interestExpense 14M 13M 12M 12M 11M 10M
depreciationAndAmortization 23M 25M 25M 26M 80M -23M
ebitda 87M 64M 55M 64M 154M 55M
ebitdaratio 0.159 0.133 0.120 0.113 0.249 0.100
operatingIncome 65M 25M 29M 38M 73M 78M
operatingIncomeRatio 0.118 0.053 0.064 0.067 0.119 0.142
totalOtherIncomeExpensesNet -42M -18M -5M -12M -18M -26M
incomeBeforeTax 23M 14M 25M 26M 56M 52M
incomeBeforeTaxRatio 0.042 0.029 0.054 0.046 0.090 0.095
incomeTaxExpense -11M 3M 9M 5M 15M 14M
netIncome 34M 11M 16M 21M 41M 38M
netIncomeRatio 0.062 0.022 0.034 0.038 0.066 0.069
eps 0.640 0.200 0.300 0.400 0.760 0.720
epsdiluted 0.630 0.200 0.290 0.390 0.740 0.700
weightedAverageShsOut 53M 53M 54M 53M 54M 53M
weightedAverageShsOutDil 54M 54M 54M 54M 55M 54M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-30 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-10-01
symbol MASI MASI MASI MASI MASI MASI
reportedCurrency USD USD USD USD USD USD
cik 937 556 937 556 937 556 937 556 937 556 937 556
fillingDate 2024-02-28 2023-11-08 2023-08-08 2023-05-10 2023-03-01 2022-11-09
acceptedDate 2024-02-28 17:31:44 2023-11-07 19:39:46 2023-08-08 17:30:23 2023-05-09 21:23:27 2023-03-01 07:24:40 2022-11-08 17:47:45
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 166M 124M 151M 174M 203M 220M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 166M 124M 151M 174M 203M 220M
netReceivables 421M 357M 349M 411M 505M 372M
inventory 545M 585M 543M 504M 501M 495M
otherCurrentAssets 100M 172M 166M 172M 4M 159M
totalCurrentAssets 1 232M 1 238M 1 208M 1 261M 1 309M 1 246M
propertyPlantEquipmentNet 485M 415M 410M 402M 472M 372M
goodwill 408M 400M 411M 422M 445M 446M
intangibleAssets 1 205M 630M 666M 690M 723M 709M
goodwillAndIntangibleAssets 1 612M 1 030M 1 077M 1 112M 1 168M 1 155M
longTermInvestments 112M 125M 14M 14M 14M 14M
taxAssets 107M 88M 88M 112M 103M 57M
otherNonCurrentAssets -507M 101M 214M 215M 145M 213M
totalNonCurrentAssets 1 810M 1 758M 1 803M 1 855M 1 902M 1 811M
otherAssets 0 0 0 0 300 000 0
totalAssets 3 042M 2 996M 3 011M 3 116M 3 211M 3 056M
accountPayables 252M 284M 266M 249M 277M 268M
shortTermDebt 53M 56M 50M 54M 34M 32M
taxPayables 16M 56M 68M 51M 72M 51M
deferredRevenue 37M 73M 74M 82M 36M 78M
otherCurrentLiabilities 222M 166M 183M 198M 283M 210M
totalCurrentLiabilities 564M 579M 572M 583M 630M 587M
longTermDebt 872M 910M 889M 898M 995M 951M
deferredRevenueNonCurrent 26M 26M 26M 26M 25M 23M
deferredTaxLiabilitiesNonCurrent 136M 112M 119M 168M 164M 139M
otherNonCurrentLiabilities 79M 93M 97M 111M 58M 839M
totalNonCurrentLiabilities 1 113M 1 142M 1 131M 1 202M 1 242M 1 217M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 46M 60M 65M 78M 72M 73M
totalLiabilities 1 677M 1 720M 1 703M 1 785M 1 872M 1 804M
preferredStock 0 0 0 0 0 0
commonStock 100 000 100 000 100 000 100 000 100 000 100 000
retainedEarnings 1 796M 1 762M 1 751M 1 736M 1 714M 1 674M
accumulatedOtherComprehensiveIncomeLoss -45M -91M -48M -18M 12M -27M
othertotalStockholdersEquity -386M -396M -396M -388M -387M -394M
totalStockholdersEquity 1 365M 1 276M 1 308M 1 330M 1 339M 1 253M
totalEquity 1 365M 1 276M 1 308M 1 330M 1 339M 1 253M
totalLiabilitiesAndStockholdersEquity 3 042M 2 996M 3 011M 3 116M 3 211M 3 056M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 3 042M 2 996M 3 011M 3 116M 3 211M 3 056M
totalInvestments 112M 125M 14M 14M 14M 14M
totalDebt 970M 910M 889M 898M 1 029M 951M
netDebt 804M 786M 738M 723M 826M 732M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-30 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-10-01
symbol MASI MASI MASI MASI MASI MASI
reportedCurrency USD USD USD USD USD USD
cik 937 556 937 556 937 556 937 556 937 556 937 556
fillingDate 2024-02-28 2023-11-08 2023-08-08 2023-05-10 2023-03-01 2022-11-09
acceptedDate 2024-02-28 17:31:44 2023-11-07 19:39:46 2023-08-08 17:30:23 2023-05-09 21:23:27 2023-03-01 07:24:40 2022-11-08 17:47:45
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 34M 11M 16M 21M 41M 38M
depreciationAndAmortization 23M 25M 25M 26M 80M -23M
deferredIncomeTax -36M 8M 100 000 0 0 0
stockBasedCompensation 9M -1M -9M 7M 6M 14M
changeInWorkingCapital 43M -50M -9M -55M -95M -19M
accountsReceivables 14M -11M 61M 35M -72M -22M
inventory 24M -48M -38M -7M -85M -3M
accountsPayables -23M 15M 15M -27M -9M 29M
otherWorkingCapital 29M -6M -47M -56M 71M -23M
otherNonCashItems 4M 500 000 400 000 500 000 -38M 1 000 000
netCashProvidedByOperatingActivities 77M -7M 24M 400 000 -7M 10M
investmentsInPropertyPlantAndEquipment -25M -22M -22M -18M -6M -9M
acquisitionsNet 8M 0 0 8M -15M 500 000
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites -8M -300 000 -300 000 -400 000 -2M 1M
netCashUsedForInvestingActivites -25M -22M -22M -11M -23M -8M
debtRepayment -36M -42M -40M -72M -39M 0
commonStockIssued 300 000 700 000 1M 5M 1M 2M
commonStockRepurchased 0 0 -600 000 0 -100 000 0
dividendsPaid 0 0 -600 000 0 0 0
otherFinancingActivites -200 000 61M 35M 32M 33M 27M
netCashUsedProvidedByFinancingActivities -36M 19M -5M -35M -5M 29M
effectOfForexChangesOnCash 20M -16M -19M 17M 22M -30M
netChangeInCash 39M -26M -23M -29M -13M 2M
cashAtEndOfPeriod 166M 132M 159M 181M 210M 222M
cashAtBeginningOfPeriod 127M 159M 181M 210M 222M 221M
operatingCashFlow 77M -7M 24M 400 000 -7M 10M
capitalExpenditure -25M -22M -22M -18M -6M -9M
freeCashFlow 52M -29M 2M -18M -13M 1 000 000
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-27 21:05 ET
Masimo Reports Fourth Quarter and Full-Year 2023 Financial Results
2024-02-20 13:00 ET
Masimo and UCHealth Announce a Clinical Monitoring Partnership to Improve Care with Telehealth
2024-02-13 14:00 ET
Masimo Announces the First FDA-cleared “Over-the-Counter” Fingertip Pulse Oximeter
2024-02-08 21:15 ET
New Peer-Reviewed Study Finds That Masimo SET® Pulse Oximetry Measures Accurately on Both Black and White People Even During Low Perfusion
2024-01-17 22:44 ET
Masimo Announces Reinstatement of Import Ban on Infringing Apple Watches
2024-01-16 21:05 ET
Masimo Announces New Member of the Board of Directors
2024-01-10 13:00 ET
Masimo Announces Select Preliminary 2023 Financial Results and 2024 Guidance
2023-12-18 17:48 ET
Masimo Receives FDA Clearance for Stork™ Baby Monitoring System
2023-12-11 07:00 ET
New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation
2023-11-27 14:00 ET
Masimo to Present in Piper Sandler 35th Annual Healthcare Conference
2023-11-17 21:24 ET
Masimo W1™ Medical Watch Receives FDA 510(k) Clearance for Over-the-Counter and Prescription Use
2023-11-09 14:00 ET
Masimo to Present in Jefferies London Healthcare Conference
2023-11-08 13:00 ET
GE HealthCare and Masimo Collaborate to Bring Masimo SET® Pulse Oximetry to the Wireless and Wearable GE HealthCare Portrait Mobile Platform
2023-11-07 23:41 ET
Masimo Announces New Member of the Board of Directors
2023-11-07 21:05 ET
Masimo Reports Third Quarter 2023 Financial Results
2023-10-26 23:31 ET
United States International Trade Commission Issues Exclusion Order for Infringing Apple Watches, Finding that Apple Violated U.S. Trade Laws
2023-10-24 20:05 ET
Masimo to Report Third Quarter 2023 Financial Results after Market Close on Tuesday, November 7
2023-10-13 12:00 ET
Masimo ORi™ Granted De Novo as the First and Only FDA-Cleared Noninvasive and Continuous Parameter to Provide Insight into Hyperoxia Under Supplemental Oxygen
2023-10-09 06:00 ET
Masimo Receives EU MDR CE Mark for LiDCO® Module for Hemodynamic Monitoring
2023-09-07 13:00 ET
Masimo to Present in Wells Fargo Healthcare Conference
2023-08-31 12:00 ET
Franciscan Missionaries of Our Lady Health System and Masimo Sign Multi-year, System-wide Monitoring Agreement
2023-08-23 12:00 ET
Masimo Announces Full Market Release of Stork™ Smart Home Baby Monitor
2023-08-21 06:00 ET
New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Elderly Patients Undergoing Gastrointestinal Surgery
2023-08-08 20:05 ET
Masimo Reports Second Quarter 2023 Financial Results
2023-08-07 12:00 ET
New Study Finds That Masimo SedLine® Patient State Index (PSi) Has the Potential to Improve Brain Monitoring for Patients Sedated with Dexmedetomidine
2023-07-17 20:34 ET
Masimo Announces Preliminary Second Quarter 2023 Revenue Results
2023-06-26 21:26 ET
Politan Announces Shareholders Have Overwhelmingly Elected Both Its Director Nominees to Masimo's Board
2023-06-22 06:00 ET
Hospital La Fe Expands Telehealth Program with Masimo W1™ for Preoperative Patients
2023-06-22 01:15 ET
Masimo and Clinton Foundation Host Roundtable Addressing Overdose and Addiction Crisis
2023-06-20 13:10 ET
Masimo Board of Directors Encourages Stockholders to Protect Their Investment by Voting FOR H Michael Cohen and Julie Shimer, Ph.D., on the WHITE Proxy Card
2023-06-20 12:00 ET
Masimo Expands Into the Personalized Hearables Market with Denon PerL™ True Wireless Earbuds, Featuring Masimo Adaptive Acoustic Technology™ (AAT™)
2023-06-15 15:10 ET
Leading Proxy Advisory Firm Glass Lewis Recommends Masimo Shareholders Vote FOR Both of Politan’s Director Nominees
2023-06-13 18:50 ET
Leading Proxy Advisory Firm ISS Recommends Masimo Shareholders Vote FOR Both of Politan’s Director Nominees
2023-06-13 13:05 ET
Masimo Board of Directors Highlights Value of Company’s Mission-Driven Innovation in Letter to Stockholders
2023-06-12 12:00 ET
Community Health System Expands Use of Multiple Masimo Technologies, System-wide
2023-06-12 11:00 ET
Politan Nominees Michelle Brennan and Quentin Koffey Send Letter to Masimo Shareholders
2023-06-08 13:55 ET
Lausanne University Hospital (CHUV) Anesthesiology Department Adopts Masimo W1™ for Use in Preoperative Patient Assessment
2023-06-06 13:05 ET
Masimo Chairman and CEO Joe Kiani Waives Rights Under Director Change-in-Control Provision
2023-06-05 20:50 ET
Politan Comments on Masimo’s Recent Board Announcement
2023-06-05 20:05 ET
Masimo to Present in Jefferies Healthcare Conference
2023-06-05 12:00 ET
Masimo Announces FDA 510(k) Clearance of Radius VSM™
2023-06-02 13:06 ET
Masimo Board of Directors Authorizes Appointment of Michelle Brennan as Sixth Director Pending Stockholder Approval of Board Expansion and Election of Company Nominees
2023-06-01 13:05 ET
Masimo Board of Directors Sets the Record Straight on False and Misleading Claims
2023-05-31 13:05 ET
Masimo Files Investor Presentation Highlighting Track Record of Success, Compelling Strategy, Responsive Governance Changes and Risks Posed by Quentin Koffey’s Agenda
2023-05-30 12:20 ET
Politan Releases Investor Presentation Detailing Why New Directors Are Needed on the Masimo Board and Responds to Company’s Disingenuous Claims
2023-05-26 10:30 ET
Masimo Board of Directors Files Definitive Proxy and Issues Letter to Stockholders
2023-05-24 12:00 ET
Masimo Announces Major Expansion of the HEOS® Platform
2023-05-23 10:00 ET
Politan Calls on Shareholders to Elect Independent Oversight to Masimo’s Board
2023-05-12 12:00 ET
Orange County Business Journal Names Masimo’s Micah Young CFO of the Year
2023-05-09 20:05 ET
Masimo Reports First Quarter 2023 Financial Results
2023-05-08 06:00 ET
Cambridge University Hospitals Expands Virtual Care Program with Masimo W1™
2023-05-02 11:00 ET
Politan Nominates Two Candidates for Masimo Board
2023-05-01 12:00 ET
Masimo Stork™ Delivers State-of-the-Art Baby Monitoring to the Home
2023-04-25 13:00 ET
Masimo to Report First Quarter 2023 Financial Results After Market Close on Tuesday, May 9
2023-04-18 12:00 ET
Masimo Announces FDA Clearance of the Rad-G® with Temperature
2023-04-03 12:00 ET
Masimo Opioid Halo™ Granted De Novo for the First and Only FDA-Authorized Opioid Overdose Prevention and Alert System
2023-03-28 12:00 ET
Masimo Unveils the Future of Health Tracking and Smart Wearables with the Pre-Sale Launch of the Freedom™ Smartwatch
2023-03-23 13:00 ET
Masimo Announces Changes to Governance Structure and Practices
2023-03-15 07:00 ET
European Society of Anaesthesiology and Intensive Care (ESAIC) Recommends Noninvasive, Continuous Hemoglobin Monitoring
2023-03-09 07:00 ET
New Study Finds That Masimo PVi® Reliably Predicted Fluid Responsiveness in Young Children Undergoing Neurosurgery
2023-03-07 13:00 ET
Masimo and Temple Health Form Innovation Collaboration with Focus on Hospital Automation and Telehealth Initiatives
2023-03-06 15:28 ET
New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Adult Neurosurgical Patients
2023-03-03 13:00 ET
CalSTRS Joins Politan Capital Management in Legal Action Against Masimo CEO’s Employment Agreement
2023-03-02 14:00 ET
Masimo to Present in 44th Annual Raymond James Institutional Investors Conference
2023-02-28 21:05 ET
Masimo Reports Fourth Quarter and Full-Year 2022 Financial Results
2023-02-21 07:00 ET
New Study Evaluates the Utility of Masimo ORi™ in Reducing Hyperoxemia During Laparoscopic Gastrectomy
2023-02-15 13:00 ET
Masimo Centroid® Receives Innovative Technology Designation from Vizient
2023-02-14 14:00 ET
Masimo to Report Fourth Quarter and FY 2022 Financial Results After Market Close on Tuesday, February 28
2023-01-30 13:00 ET
Masimo Announces the Limited Market Release of Visual Clinical Activity Monitoring (VCAM™)
2023-01-23 07:00 ET
Researchers Harness the Power of Masimo Root®’s Advanced Multimodal Monitoring Capabilities to Study the Impact of Different Ventilatory Strategies on Brain Oxygenation During Thoracoscopic Surgery
2023-01-18 14:00 ET
Masimo and Philips Expand Partnership to Improve Telehealth for Patients and Clinicians Around the World with the Masimo W1™ Watch
2023-01-11 01:15 ET
ITC Judge Rules Apple Violated U.S. Trade Laws by Infringing Masimo Pulse Oximeter Patent
2023-01-09 07:00 ET
New Study Evaluates the Performance of Masimo SpHb® Noninvasive Spot-Check Hemoglobin in the Emergency Department
2023-01-05 07:00 ET
New Study Finds That Masimo Patient SafetyNet™ Helped Clinicians Reduce CPR Events and Rates, Improve CPR Success Rate, and Reduce Hospital Length of Stay and Mortality
2023-01-04 21:05 ET
Masimo to Present in 41st Annual J.P. Morgan Healthcare Conference
2023-01-03 07:00 ET
New Prospective Study Evaluates the Accuracy of Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring During Elective Cesarean Section
2022-12-13 13:00 ET
Masimo Takes Major Step in Connecting the Hospital to the Home
2022-12-13 12:00 ET
Masimo Hosts Investor Day to Detail Next Phase of Its Growth Trajectory
2022-12-12 07:00 ET
Masimo Announces Limited Market Release of Sepsis Index
2022-12-07 13:00 ET
Masimo Announces Full Market Release of Hydration Index for the Masimo W1™ Advanced Health Tracking Watch
2022-11-30 07:00 ET
New Prospective Study Finds That Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring Can Help Provide Effective Blood Management in Patients Undergoing Major Surgery
2022-11-22 14:00 ET
Masimo to Present in Piper Sandler 34th Annual Healthcare Conference
2022-11-21 13:00 ET
Peer-Reviewed Study Finds That Masimo SET® Pulse Oximetry Has No Clinically Significant Difference in Accuracy or Bias Between Black and White People
2022-11-17 13:00 ET
Federal Court Rules for Masimo in Suit Against Former Engineer for Unlawful Theft of Company’s Pulse Oximeter Trade Secrets
2022-11-09 21:05 ET
Masimo to Present in Stifel 2022 Healthcare Conference
2022-11-08 21:05 ET
Masimo Reports Third Quarter 2022 Financial Results
2022-10-25 20:05 ET
Masimo to Report Third Quarter 2022 Financial Results after Market Close on Tuesday, November 8
2022-10-21 17:10 ET
Masimo Sets the Record Straight on Bylaw Amendments
2022-10-21 14:00 ET
Politan Capital Management Takes Legal Action in Response to Masimo’s Attempts to Eliminate Stockholder Rights
2022-09-19 12:00 ET
Masimo Appoints New Leader for Consumer Division
2022-08-31 12:00 ET
Medical Pioneer Masimo Announces the Full Market Consumer Release of the Masimo W1™, the First Watch to Offer Accurate, Continuous Health Data
2022-08-09 20:05 ET
Masimo Reports Second Quarter 2022 Financial Results
2022-07-26 20:15 ET
Masimo to Report Second Quarter 2022 Financial Results after Market Close on Tuesday, August 9
2022-07-20 14:21 ET
Randomized Controlled Study Finds Masimo SedLine® Brain Function Monitoring Can Help Guide Anesthesia in Children Undergoing Minor Surgery
2022-07-05 12:00 ET
Two-part Study Finds That Remote Patient Monitoring with Masimo SafetyNet® Reduced Length of Hospital Stay for COVID-19 Patients
2022-05-23 06:00 ET
New Study Finds That Masimo PVi® May Be Useful in Helping ER Doctors Determine the Severity of Asthma Attacks in Pediatric Patients
2022-05-03 20:05 ET
Masimo Reports First Quarter 2022 Financial Results
2022-05-02 12:00 ET
Medical Monitoring Pioneer Announces the Limited Market Release of the Masimo W1™ Watch for Consumers
2022-04-25 12:00 ET
Masimo SedLine® Brain Function Monitoring Reduced the Use of Anesthetic Agents and Opioids in a Study on Patients Undergoing Cardiac Surgery
2022-04-18 12:00 ET
New JAMA Article Highlights the Outcome and Safety Benefits of Remote Patient Monitoring During the Pandemic and Beyond
2022-04-12 13:00 ET
Masimo Closes Acquisition of Sound United
2022-03-30 20:15 ET
Masimo Announces Certain Preliminary First Quarter 2022 Financial Results and Reaffirms Full-Year 2022 Revenue Guidance
2022-03-28 06:00 ET
New Study Finds That Noninvasive and Continuous Hemoglobin Improved Transfusion Management and Outcomes in Pediatric Patients
2022-03-14 12:00 ET
Masimo Debuts Telehealth for Patient SafetyNet™ at HIMSS 2022 Global Health Conference
2022-02-28 13:00 ET
Masimo Announces FDA Clearance of Pediatric Indication for SedLine® Brain Function Monitoring and the SedLine Pediatric EEG Sensor
2022-02-15 22:16 ET
Sound United Enters into Agreement to Be Acquired by Masimo Corporation
2022-02-15 21:05 ET
Masimo Reports Fourth Quarter and Full-Year 2021 Financial Results and Announces Agreement to Acquire Sound United
2022-02-10 13:00 ET
Masimo Adds Telehealth to Its SafetyNet® Telemonitoring System
2022-02-07 20:31 ET
Temple University Hospital Adopts Masimo Centroid™
2022-01-17 18:22 ET
Retrospective Study Finds That Masimo SET® Pulse Oximetry Has No Difference in Accuracy or Bias Between Black People and White People
2022-01-11 14:00 ET
Masimo Announces Select Preliminary Full-Year 2021 Financial Results and 2022 Guidance
2021-12-13 07:00 ET
New Study Suggests That Masimo SedLine® Brain Function Monitoring May Aid Early Identification of Patients at Risk of Developing Postoperative Delirium
2021-11-29 07:00 ET
Masimo Rad-G® Helps Clinicians Identify Pediatric Pneumonia in Large Field Trial in India
2021-11-23 14:00 ET
Masimo to Present in Piper Sandler 33rd Annual Healthcare Conference
2021-11-15 07:00 ET
New Study Finds That Use of Masimo SedLine® PSi and DSA May Significantly Reduce Postoperative Delirium
2021-11-11 14:00 ET
Masimo to Present in Stifel 2021 Virtual Healthcare Conference
2021-11-08 07:00 ET
Masimo Root® with a Multimodal Brain Monitoring Algorithm May Improve Postoperative Neurocognition in Elderly Patients
2021-11-01 07:00 ET
Masimo Launches Dual SET® Pulse Oximetry
2021-10-26 20:05 ET
Masimo Reports Third Quarter 2021 Financial Results
2021-10-18 12:00 ET
New Study Recommends the Use of Masimo PVi® to Guide Fluid Administration During Major Oncosurgery with Lung Ultrasonography
2021-10-12 20:05 ET
Masimo to Report Third Quarter 2021 Financial Results After Market Close on Tuesday, October 26
2021-10-04 12:00 ET
Masimo and University Hospitals Partner to Combat Nurse Burnout
2021-09-26 23:00 ET
New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates
2021-09-22 21:00 ET
Masimo CEO Joe Kiani Appointed to President’s Council of Advisors on Science and Technology
2021-09-13 06:00 ET
Masimo Launches Single-patient-use rainbow® SuperSensor™
2021-09-08 13:00 ET
Masimo to Present in Morgan Stanley 19th Annual Global Healthcare Conference
2021-09-06 06:00 ET
New Study Investigates the Ability of Masimo ORi™ to Provide Early Warning of Hypoxemia During Endotracheal Intubation in ICU Patients
2021-08-31 07:00 ET
Masimo Partners with Penington Institute to Raise Awareness of Harm from Prescription Opioid Overdose
2021-08-30 06:00 ET
Masimo SafetyNet Alert™ Launches in Western Europe
2021-08-26 12:00 ET
Society for the Advancement of Patient Blood Management (SABM) Publication Recommends Continuous Hemoglobin Monitoring
2021-08-23 06:00 ET
New Study Evaluates the Use of Masimo PVi® to Monitor Volume Status in Spontaneously Breathing Hemodialysis Patients
2021-08-16 12:00 ET
New Study Evaluates the Use of Masimo Bridge® As an Alternative to Opioids
2021-07-27 20:05 ET
Masimo Reports Second Quarter 2021 Financial Results
2021-07-19 12:00 ET
Masimo Introduces the MX-7™ rainbow SET® Technology Board for Original Equipment Manufacturing Partners
2021-07-13 20:05 ET
Masimo to Report Second Quarter 2021 Financial Results after Market Close on Tuesday, July 27
2021-07-06 06:00 ET
New Study Evaluates the Ability of Masimo SedLine® Brain Function Monitoring to Predict Neurological Outcomes and Long-term Survival in Post-Cardiac Arrest ICU Patients
2021-06-21 12:00 ET
Masimo Announces FDA 510(k) Clearance of Radius Tº™ for Prescription and Over-the-Counter (OTC) Use
2021-06-14 06:00 ET
New Study Investigates the Impact of ORi-Guided Oxygen Titration on Hyperoxemia-Mediated Morbidity During One-Lung Ventilation
2021-05-19 20:05 ET
Masimo to Present in UBS Global Healthcare Virtual Conference
2021-05-17 06:00 ET
New Study Assesses the Effects of Masimo Patient SafetyNet™ on Nursing Workflows in the General Ward
2021-05-13 12:00 ET
Spacelabs Healthcare Partners With Masimo to Bring Advanced Measurements to Spacelabs Patient Monitors
2021-05-13 12:00 ET
Spacelabs Healthcare Partners with Masimo to Bring Advanced Measurements to Spacelabs Patient Monitors
2021-05-10 06:00 ET
Study Investigates the Ability of Masimo O3® to Aid in Monitoring Septic Shock ICU Patients and Predicting Mortality
2021-05-03 06:00 ET
Study Investigates the Ability of Masimo PVi® to Predict Preload Responsiveness in Patients On Nasal High-Flow Therapy
2021-04-26 20:05 ET
Masimo Reports First Quarter 2021 Financial Results
2021-04-19 20:16 ET
Masimo Reschedules Date of First Quarter 2021 Financial Results Conference Call
2021-04-14 20:00 ET
Masimo to Report First Quarter 2021 Financial Results after Market Close on Tuesday, April 27
2021-04-12 12:00 ET
Masimo Announces FDA Clearance of Radius PCG™ for the Root® Patient Monitoring and Connectivity Platform
2021-04-06 13:00 ET
Masimo to Present in 20th Annual Needham Healthcare Conference
2021-04-06 06:00 ET
Study Investigates the Effects of Ventilatory Rescue Therapies on the Cerebral Oxygenation of COVID-19 Patients Using Masimo O3®
2021-03-29 06:00 ET
Study Investigates the Impact of Automating Respiration Rate Measurement Using Masimo Rad-G™ with RRp®
2021-03-22 07:00 ET
Sri Lankan Study Expands Evidence Demonstrating the Benefits of Critical Congenital Heart Disease (CCHD) Screening Using Masimo SET® Pulse Oximetry
2021-03-15 07:00 ET
New Study Evaluates the Ability of Masimo EMMA® Capnography to Assess the Respiratory Status of Children With Tracheostomy
2021-03-08 05:00 ET
Masimo Monitoring Solutions Promote Newborn and Maternal Safety
2021-03-02 07:00 ET
Masimo Announces CE Marking of the Rad-G™ with Temperature
2021-02-24 14:00 ET
Masimo to Present in Raymond James 42nd Annual Institutional Investors Conference
2021-02-23 21:05 ET
Masimo Reports Fourth Quarter and Full-Year 2020 Financial Results
2021-02-23 13:00 ET
Masimo Announces U.S. Release of softFlow® High-Flow Nasal Cannula Therapy
2021-02-16 14:00 ET
Masimo to Report Fourth Quarter and Full Year 2020 Financial Results after Market Close on Tuesday, February 23
2021-02-15 13:00 ET
Masimo Announces Full Market Release of Masimo SafetyNet-OPEN™
2021-02-10 14:00 ET
Masimo to Present in BTIG MedTech and Digital Health Conference
2021-02-02 13:00 ET
Masimo Expands Suite of Advanced Measurements Through Acquisition of UK-Based LiDCO Group Plc
2021-01-19 13:00 ET
Masimo Announces the iSirona™ Connectivity Hub
2021-01-13 21:11 ET
Masimo Announces Select Preliminary Full-Year 2020 Financial Results and 2021 Guidance
2020-12-21 13:00 ET
Masimo Helps Clinicians at Renown Health Manage the COVID-19 Surge
2020-12-14 07:00 ET
Researchers Use Masimo ORi™, Oxygen Reserve Index, to Help Suppress Postoperative Hyperoxia in Patients Undergoing Breast Surgery
2020-12-10 07:00 ET
New Study Associates Masimo SpHb®, Noninvasive and Continuous Hemoglobin Monitoring, as Part of Pediatric Patient Blood Management, with Reduced ICU Stays and Postoperative Transfusion
2020-12-07 14:20 ET
Masimo’s COVID-19 Response Efforts Highlighted at California Life Sciences Association’s Pantheon 2020
2020-11-30 14:00 ET
Masimo to Present in Piper Sandler Virtual Healthcare Conference
2020-11-30 07:00 ET
Study Comparing Two Noninvasive Indicators of Fluid Responsiveness on Mechanically Ventilated Patients Finds Masimo PVi® Effective and Advantageous
2020-11-16 14:00 ET
Masimo to Present in Stifel Virtual Healthcare Conference
2020-11-16 07:00 ET
Study Investigates Effects of Patient Blood Management Program with Masimo SpHb®, Noninvasive, Continuous Hemoglobin Monitoring, on Postoperative Cancer Patients
2020-11-09 13:00 ET
Masimo Founder and CEO and Co-Inventor of Measure-Through-Motion Pulse Oximetry, Joe Kiani, Awarded by the Ibero-American Society of Neonatology for Improvements to Neonatal Health in Latin America
2020-11-02 07:00 ET
Masimo Announces Limited Market Release of Radius VSM™
2020-10-27 20:05 ET
Masimo Reports Third Quarter 2020 Financial Results
2020-10-20 13:00 ET
Masimo to Report Third Quarter 2020 Financial Results after Market Close on Tuesday, October 27
2020-10-19 12:00 ET
Dr. Augusto Sola, Masimo VP of Medical Affairs for Neonatology, Honored by the American Academy of Pediatrics with Pioneer Award
2020-10-12 06:00 ET
Researchers Use Masimo ORi™, Oxygen Reserve Index, to Predict the Need for Postoperative Oxygen Therapy in Pediatric Patients with Obstructive Sleep Apnea
2020-10-06 21:00 ET
Masimo Announces Select Preliminary Third Quarter 2020 Financial Results and Updated Full-Year 2020 Guidance
2020-10-05 12:00 ET
Masimo Announces Consumer Launch of the Radius Tº™ Continuous Thermometer, a More Convenient Way to Keep Track of Fever
2020-09-28 12:00 ET
Masimo Announces FDA Clearance of the Rad-G™ Pulse Oximeter
2020-09-14 13:00 ET
Masimo to Present in Morgan Stanley 18th Annual Global Healthcare Conference
2020-09-02 16:47 ET
Modern Healthcare Honors Dr. Peter Pronovost as a Top 25 Innovator for Spearheading Remote Monitoring Program at University Hospitals Using Masimo’s Technology
2020-08-31 13:18 ET
Masimo O3® Regional Oximetry Receives FDA Clearance for Somatic Applications and Measurement of Relative Changes in Cerebral Hemoglobin
2020-08-19 06:00 ET
New Studies Investigate the Accuracy of Noninvasive, Continuous Hemoglobin Monitoring with Masimo SpHb® on Neonates
2020-08-14 12:00 ET
Masimo PVi® Receives FDA Clearance as an Indicator of Fluid Responsiveness on Mechanically Ventilated Patients
2020-08-03 12:00 ET
New Blinded Observational Study Shows Greater Depth of Patient Sedation Than Intended During Procedural Colonoscopy
2020-07-30 13:08 ET
Masimo Named NBA Supplier of Pulse Oximetry
2020-07-28 20:05 ET
Masimo Reports Second Quarter 2020 Financial Results
2020-07-27 12:00 ET
Masimo Expands the Masimo SafetyNet™ Remote Patient Management Solution with Continuous Body Temperature Measurement
2020-07-20 06:00 ET
New Study Expands Evidence Demonstrating the Benefits of Critical Congenital Heart Disease (CCHD) Screening Using Masimo SET® Pulse Oximetry
2020-07-14 13:00 ET
Masimo to Report Second Quarter 2020 Financial Results after Market Close on Tuesday, July 28
2020-07-14 12:00 ET
Masimo Announces UniView: 60™ Digital Charting Solution
2020-07-06 06:00 ET
Study Investigates Accuracy of Respiration Rate Obtained From Pulse Oximetry on Pediatric Patients Using Masimo RRp®
2020-01-14 14:05 ET
Masimo Announces Select Preliminary Full-Year 2019 Financial Results and 2020 Guidance

SEC forms

Show financial reports only

SEC form 10
2024-02-28 17:31 ET
Masimo published news for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Masimo published news for 2023 q4
SEC form 8
2024-02-27 16:12 ET
Masimo published news for 2023 q4
SEC form 8
2024-02-27 16:12 ET
Masimo published news for 2023 q4
SEC form 8
2024-02-27 16:12 ET
Masimo reported for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Masimo published news for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Masimo published news for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Masimo published news for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Masimo published news for 2023 q4
SEC form 10
2023-11-08 00:00 ET
Masimo reported for 2023 q3
SEC form 10
2023-11-07 19:39 ET
Masimo reported for 2023 q3
SEC form 8
2023-11-07 16:19 ET
Masimo reported for 2023 q3
SEC form 10
2023-08-08 17:30 ET
Masimo reported for 2023 q2
SEC form 6
2023-08-08 16:07 ET
Masimo reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Masimo reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Masimo reported for 2023 q2
SEC form 6
2023-07-17 16:35 ET
Masimo published news for 2023 q2
SEC form 8
2023-07-17 00:00 ET
Masimo published news for 2023 q2
SEC form 6
2023-06-29 16:35 ET
Masimo published news for 2023 q1
SEC form 6
2023-06-28 16:51 ET
Masimo published news for 2023 q1
SEC form 6
2023-06-27 18:17 ET
Masimo published news for 2023 q1
SEC form 6
2023-06-06 09:07 ET
Masimo published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Masimo reported for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Masimo reported for 2023 q1
SEC form 6
2023-03-27 16:18 ET
Masimo published news for 2022 q4
SEC form 6
2023-03-23 09:02 ET
Masimo published news for 2022 q4
SEC form 10
2023-03-01 07:24 ET
Masimo published news for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Masimo published news for 2022 q4
SEC form 6
2023-02-28 16:22 ET
Masimo published news for 2022 q4
SEC form 6
2023-02-28 16:19 ET
Masimo published news for 2022 q4
SEC form 6
2023-02-28 16:17 ET
Masimo published news for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Masimo published news for 2022 q4
SEC form 6
2023-02-06 08:00 ET
Masimo published news for 2022 q4
SEC form 6
2023-01-10 21:53 ET
Masimo published news for 2022 q4
SEC form 6
2022-12-13 16:18 ET
Masimo published news for 2022 q3
SEC form 6
2022-12-13 07:02 ET
Masimo published news for 2022 q3
SEC form 6
2022-12-01 16:20 ET
Masimo published news for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Masimo reported for 2022 q3
SEC form 10
2022-11-08 17:47 ET
Masimo reported for 2022 q3
SEC form 6
2022-11-08 16:19 ET
Masimo published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Masimo reported for 2022 q3
SEC form 6
2022-09-26 18:43 ET
Masimo published news for 2022 q2
SEC form 6
2022-09-19 08:03 ET
Masimo published news for 2022 q2
SEC form 6
2022-09-09 08:47 ET
Masimo published news for 2022 q2
SEC form 10
2022-08-10 00:00 ET
Masimo reported for 2022 q2
SEC form 10
2022-08-09 20:52 ET
Masimo reported for 2022 q2
SEC form 6
2022-08-09 16:16 ET
Masimo published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Masimo reported for 2022 q2
SEC form 6
2022-07-13 09:02 ET
Masimo published news for 2022 q2
SEC form 6
2022-06-24 16:07 ET
Masimo published news for 2022 q1
SEC form 6
2022-06-17 18:02 ET
Masimo published news for 2022 q1
SEC form 6
2022-05-31 16:19 ET
Masimo published news for 2022 q1
SEC form 6
2022-05-20 16:28 ET
Masimo published news for 2022 q1
SEC form 10
2022-05-03 16:51 ET
Masimo reported for 2022 q1
SEC form 6
2022-05-03 16:33 ET
Masimo published news for 2022 q1
SEC form 10
2022-05-03 00:00 ET
Masimo reported for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Masimo reported for 2022 q1
SEC form 6
2022-04-14 16:08 ET
Masimo published news for 2022 q1
SEC form 6
2022-04-12 09:03 ET
Masimo published news for 2022 q1
SEC form 6
2022-04-04 21:01 ET
Masimo published news for 2022 q1
SEC form 6
2022-03-30 16:17 ET
Masimo published news for 2021 q4
SEC form 8
2022-03-30 00:00 ET
Masimo published news for 2021 q4
SEC form 10
2022-02-16 00:00 ET
Masimo published news for 2021 q4
SEC form 10
2022-02-15 18:53 ET
Masimo published news for 2021 q4
SEC form 6
2022-02-15 16:48 ET
Masimo published news for 2021 q4
SEC form 6
2022-02-15 16:40 ET
Masimo published news for 2021 q4
SEC form 8
2022-02-15 00:00 ET
Masimo published news for 2021 q4
SEC form 6
2022-01-14 16:24 ET
Masimo published news for 2021 q4
SEC form 6
2022-01-11 09:03 ET
Masimo published news for 2021 q4
SEC form 8
2022-01-11 00:00 ET
Masimo published news for 2021 q4
SEC form 10
2021-10-26 17:08 ET
Masimo published news for 2021 q3
SEC form 6
2021-10-26 16:08 ET
Masimo published news for 2021 q3
SEC form 10
2021-10-26 00:00 ET
Masimo published news for 2021 q3
SEC form 8
2021-10-26 00:00 ET
Masimo published news for 2021 q3
SEC form 10
2021-07-27 17:05 ET
Masimo published news for 2021 q2
SEC form 6
2021-07-27 16:37 ET
Masimo published news for 2021 q2
SEC form 10
2021-07-27 00:00 ET
Masimo published news for 2021 q2
SEC form 8
2021-07-27 00:00 ET
Masimo published news for 2021 q2
SEC form 6
2021-06-01 17:28 ET
Masimo published news for 2021 q1
SEC form 6
2021-05-06 16:11 ET
Masimo published news for 2021 q1
SEC form 10
2021-04-27 00:00 ET
Masimo published news for 2021 q1
SEC form 10
2021-04-26 20:28 ET
Masimo published news for 2021 q1
SEC form 6
2021-04-26 16:08 ET
Masimo published news for 2021 q1
SEC form 8
2021-04-26 00:00 ET
Masimo published news for 2021 q1
SEC form 6
2021-04-15 09:12 ET
Masimo published news for 2021 q1
SEC form 6
2021-04-07 17:06 ET
Masimo published news for 2021 q1
SEC form 6
2021-03-02 16:32 ET
Masimo published news for 2020 q4
SEC form 6
2021-02-26 06:14 ET
Masimo published news for 2020 q4
SEC form 10
2021-02-23 17:13 ET
Masimo published news for 2020 q4
SEC form 6
2021-02-23 16:13 ET
Masimo published news for 2020 q4
SEC form 6
2021-02-02 08:02 ET
Masimo published news for 2020 q4
SEC form 6
2021-01-13 16:16 ET
Masimo published news for 2020 q4
SEC form 6
2020-12-17 17:23 ET
Masimo published news for 2020 q3
SEC form 6
2020-11-05 16:26 ET
Masimo published news for 2020 q3
SEC form 6
2020-11-05 16:14 ET
Masimo published news for 2020 q3
SEC form 6
2020-11-02 17:30 ET
Masimo published news for 2020 q3
SEC form 6
2020-10-29 16:12 ET
Masimo published news for 2020 q3
SEC form 10
2020-10-27 17:18 ET
Masimo published news for 2020 q3
SEC form 6
2020-10-27 16:09 ET
Masimo published news for 2020 q3
SEC form 6
2020-10-21 17:09 ET
Masimo published news for 2020 q3
SEC form 6
2020-10-14 16:14 ET
Masimo published news for 2020 q3
SEC form 6
2020-10-09 16:13 ET
Masimo published news for 2020 q3
SEC form 6
2020-10-09 16:10 ET
Masimo published news for 2020 q3
SEC form 6
2020-10-09 16:08 ET
Masimo published news for 2020 q3
SEC form 6
2020-10-06 17:01 ET
Masimo published news for 2020 q3